Induced Pluripotent Stem Cells: Reprogramming Platforms and Applications in Cell Replacement Therapy
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
The generation of induced pluripotent stem cells (iPSCs) from differentiated mature cells is one of the most promising technologies in the field of regenerative medicine. The ability to generate patient-specific iPSCs offers an invaluable reservoir of pluripotent cells, which could be genetically engineered and differentiated into target cells to treat various genetic and degenerative diseases once transplanted, hence counteracting the risk of graft versus host disease. In this context, we review the scientific research streams that lead to the emergence of iPSCs, the roles of reprogramming factors in reprogramming to pluripotency, and the reprogramming strategies. As iPSCs serve tremendous correction potentials for various diseases, we highlight the successes and challenges of iPSCs in cell replacement therapy and the synergy of iPSCs and clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing tools in therapeutics research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y.-H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.012 · Cited by 2,662 · cited 1×
“multiple rounds of transfection may be required, these methods are relatively efficient in generating iPSCs with better safety profiles.(96,97) To improve the reprogramming process, new approaches such as microRNAs (miRNAs) have been used to enhance the reprogram-”
MethodIshino, Y., Shinagawa, H., Makino, K., Amemura, M., & Nakata, A. (1987) · Journal of Bacteriology · doi:10.1128/jb.169.12.5429-5433.1987 · Cited by 2,421
Human induced pluripotent stem cells free of vector and transgene sequences
Yu, J., Hu, K., Smuga-Otto, K., Tian, S., Stewart, R., Slukvin, I. I., & Thomson, J. A. (2009) · Science · doi:10.1126/science.1172482 · Cited by 2,386
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Kroon, E., Martinson, L. A., Kadoya, K., Bang, A. G., Kelly, O. G., Eliazer, S., Young, H., Richardson, M., Smart, N. G., Cunningham, J., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1393 · Cited by 1,843 · cited 1×
“Allogeneic transplant of human ESCs has been utilized to treat spinal cord injury in 2010,(138) dry AMD in 2016,(139,140) and type I diabetes mellitus in 2014.(141,142) In these trials, the engraftment was highly efficient, and the treated individuals did not show signs of oncogenesis.”
BackgroundGeneration of Human Induced Pluripotent Stem Cells by Direct Delivery of Reprogramming Proteins
Kim, D., Kim, C.-H., Moon, J.-I., Chung, Y.-G., Chang, M.-Y., Han, B.-S., Ko, S., Yang, E., Cha, K. Y., Lanza, R., et al. (2009) · Cell stem cell · doi:10.1016/j.stem.2009.05.005 · Cited by 1,814
Induced pluripotent stem cells generated without viral integration
Stadtfeld, M., Nagaya, M., Utikal, J., Weir, G., & Hochedlinger, K. (2008) · Science · doi:10.1126/science.1162494 · Cited by 1,683
TALENs: A widely applicable technology for targeted genome editing
Joung, J. K., & Sander, J. D. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3486 · Cited by 1,650 · cited 1×
“Targeted genome editing is broadly applicable to genetically engineer any sequence of interest in living cells or organisms.(148,149) Therefore, the combination of novel approaches in human iPSCs and CRISPR-based genome editing can”
BackgroundInduced pluripotent stem cells from a spinal muscular atrophy patient
Ebert, A. D., Yu, J., Rose, F. F., Mattis, V. B., Lorson, C. L., Thomson, J. A., & Svendsen, C. N. (2009) · Nature · doi:10.1038/nature07677 · Cited by 1,441 · cited 3×
“In an attempt for cell replacement therapy for neurodegenerative diseases, Ebert et al.24 generated the very first motor neurons differentiated from the diseased iPSC, in which the iPSC was derived from a patient’s skin fibroblast with spinal muscular atrophy.”
BackgroundInfluentialFUSAKI, N., BAN, H., NISHIYAMA, A., SAEKI, K., & HASEGAWA, M. (2009) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.85.348 · Cited by 1,411 · cited 1×
“However, it is hampered by low reprogramming efficiency.(85,86) Nevertheless, great efforts have been made to develop an improved Se-V.”
BackgroundSuppression of induced pluripotent stem cell generation by the p53–p21 pathway
Hong, H., Takahashi, K., Ichisaka, T., Aoi, T., Kanagawa, O., Nakagawa, M., Okita, K., & Yamanaka, S. (2009) · Nature · doi:10.1038/nature08235 · Cited by 1,301
Linking the p53 tumour suppressor pathway to somatic cell reprogramming
Kawamura, T., Suzuki, J., Wang, Y. V., Menendez, S., Morera, L. B., Raya, A., Wahl, G. M., & Belmonte, J. C. I. (2009) · Nature · doi:10.1038/nature08311 · Cited by 1,115
Generation of human induced pluripotent stem cells from dermal fibroblasts
Lowry, W. E., Richter, L., Yachechko, R., Pyle, A. D., Tchieu, J., Sridharan, R., Clark, A. T., & Plath, K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711983105 · Cited by 1,041 · cited 2×
“In addition, Lowry et al.(23) reported that the human cells could also be”
BackgroundA p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity
Marión, R. M., Strati, K., Li, H., Murga, M., Blanco, R., Ortega, S., Fernandez-Capetillo, O., Serrano, M., & Blasco, M. A. (2009) · Nature · doi:10.1038/nature08287 · Cited by 1,028
Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells
Wu, X., Scott, D. A., Kriz, A. J., Chiu, A. C., Hsu, P. D., Dadon, D. B., Cheng, A. W., Trevino, A. E., Konermann, S., Chen, S., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2889 · Cited by 944
A Molecular Roadmap of Reprogramming Somatic Cells into iPS Cells
Polo, J. M., Anderssen, E., Walsh, R. M., Schwarz, B. A., Nefzger, C. M., Lim, S. M., Borkent, M., Apostolou, E., Alaei, S., Cloutier, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.11.039 · Cited by 861
Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts
Shiba, Y., Gomibuchi, T., Seto, T., Wada, Y., Ichimura, H., Tanaka, Y., Ogasawara, T., Okada, K., Shiba, N., Sakamoto, K., et al. (2016) · Nature · doi:10.1038/nature19815 · Cited by 840 · cited 1×
“cient to regenerate the infarcted primate heart, although subsequent arrhythmias have been observed.(135) The first iPSC clinical trial (phase I) was conducted”
BackgroundWang, G., McCain, M. L., Yang, L., He, A., Pasqualini, F. S., Agarwal, A., Yuan, H., Jiang, D., Zhang, D., Zangi, L., et al. (2014) · Nature Medicine · doi:10.1038/nm.3545 · Cited by 837
Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse
Stadtfeld, M., Maherali, N., Breault, D. T., & Hochedlinger, K. (2008) · Cell stem cell · doi:10.1016/j.stem.2008.02.001 · Cited by 823
A nonviral minicircle vector for deriving human iPS cells
Jia, F., Wilson, K. D., Sun, N., Gupta, D. M., Huang, M., Li, Z., Panetta, N. J., Chen, Z. Y., Robbins, R. C., Kay, M. A., et al. (2010) · Nature Methods · doi:10.1038/nmeth.1426 · Cited by 734 · cited 1×
“cells using cytoplasmic RNA, episomal (self-replicating and selectable vectors),(15) or polycistronic minicircle DNA nonviral vector systems.(93) These approaches”
BackgroundLee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., et al. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.04.001 · Cited by 691 · cited 6×
“are relatively easy to use, but the reprogramming efficiency was shown to be 5–10 times lower than LV.(51) In contrast, the use of episomal plasmids and minicircle DNA vectors requires extensive optimization for future application.”
BackgroundMethodInfluentialEfficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis
Hou, Z., Zhang, Y., Propson, N. E., Howden, S. E., Chu, L.-F., Sontheimer, E. J., & Thomson, J. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313587110 · Cited by 681
Induced Pluripotent Stem Cell Generation Using a Single Lentiviral Stem Cell Cassette
Sommer, C. A., Stadtfeld, M., Murphy, G. J., Hochedlinger, K., Kotton, D. N., & Mostoslavsky, G. (2009) · Stem Cells · doi:10.1634/stemcells.2008-1075 · Cited by 676
Nakagawa, M., Taniguchi, Y., Senda, S., Takizawa, N., Ichisaka, T., Asano, K., Morizane, A., Doi, D., Takahashi, J., Nishizawa, M., et al. (2014) · Scientific Reports · doi:10.1038/srep03594 · Cited by 673 · cited 1×
“surface (known as the iMatrix-511 system) as a novel culture system with high efficiency for self-renewal of both human ESCs and human iPSCs.(111) Unfortunately, large-scale production and purification of biologically functioning recombinant laminins are laborious and costly.”
BackgroundYamanaka, S. (2009) · Cell · doi:10.1016/j.cell.2009.03.034 · Cited by 659 · cited 4×
“to mutation, as the genome of the cell is vulnerable to DNA and histone modifications.(17,78) To overcome these issues, the introduction of either synthetic RNA or messenger RNA (mRNA) encoding”
BackgroundInfluentialTargeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility
Xu, H., Wang, B., Ono, M., Kagita, A., Fujii, K., Sasakawa, N., Ueda, T., Gee, P., Nishikawa, M., Nomura, M., et al. (2019) · Cell stem cell · doi:10.1016/j.stem.2019.02.005 · Cited by 581 · cited 2×
“not only enable the HLA-C retained iPSCs to elude T cells (CD8) but also to avoid NK cell activities in vitro and in vivo.(172) In addition, the group also deleted MHC class II transactivator gene (CIITA) from”
BackgroundRecapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome
Liu, G.-H., Barkho, B. Z., Ruiz, S., Diep, D., Qu, J., Yang, S.-L., Panopoulos, A. D., Suzuki, K., Kurian, L., Walsh, C., et al. (2011) · Nature · doi:10.1038/nature09879 · Cited by 575
A High-Efficiency System for the Generation and Study of Human Induced Pluripotent Stem Cells
Maherali, N., Ahfeldt, T., Rigamonti, A., Utikal, J., Cowan, C., & Hochedlinger, K. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.08.003 · Cited by 563 · cited 2×
“Nevertheless, efforts have been made to improve the safety of this strategy.(58,59) One of the advancements made in FIG.”
BackgroundReprogramming in vivo produces teratomas and iPS cells with totipotency features
Abad, M., Mosteiro, L., Pantoja, C., Cañamero, M., Rayon, T., Ors, I., Graña, O., Megías, D., Domínguez, O., Martínez, D., et al. (2013) · Nature · doi:10.1038/nature12586 · Cited by 547
Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells
Zhou, W., & Freed, C. R. (2009) · Stem Cells · doi:10.1002/stem.201 · Cited by 538 · cited 1×
“Human and murine iPSCs have been successfully created using nonintegrating viral vectors such as adenovirus.(83,84) The iPSCs obtained from these studies demonstrated no insertion of exogenous DNA in the”
MethodThemeli, M., Kloss, C. C., Ciriello, G., Fedorov, V. D., Perna, F., Gonen, M., & Sadelain, M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2678 · Cited by 473
Taylor, C. J., Peacock, S., Chaudhry, A. N., Bradley, J. A., & Bolton, E. M. (2012) · Cell stem cell · doi:10.1016/j.stem.2012.07.014 · Cited by 428
Somers, A., Jean, J.-C., Sommer, C. A., Omari, A., Ford, C. C., Mills, J. A., Ying, L., Sommer, A. G., Jean, J. M., Smith, B. W., et al. (2010) · Stem Cells · doi:10.1002/stem.495 · Cited by 423
Xie, F., Ye, L., Chang, J. C., Beyer, A. I., Wang, J., Muench, M. O., & Kan, Y. W. (2014) · Genome Research · doi:10.1101/gr.173427.114 · Cited by 408 · cited 1×
“The corrected cells with functioning HBB gene expression were subsequently differentiated into erythroblasts.(165) Similarly, trinucleotide repeat (CAG) in Huntington gene (HTT) expression”
BackgroundSong, W. K., Park, K.-M., Kim, H.-J., Lee, J. H., Choi, J., Chong, S. Y., Shim, S. H., Del Priore, L. V., & Lanza, R. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.04.005 · Cited by 393
Herr, W., & Cleary, M. A. (1995) · Genes & Development · doi:10.1101/gad.9.14.1679 · Cited by 388
Tgfβ Signal Inhibition Cooperates in the Induction of iPSCs and Replaces Sox2 and cMyc
Maherali, N., & Hochedlinger, K. (2009) · Current Biology · doi:10.1016/j.cub.2009.08.025 · Cited by 348
Progress toward the clinical application of patient-specific pluripotent stem cells
Kiskinis, E., & Eggan, K. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40553 · Cited by 339
Efficient gene transfer to airway epithelium using recombinant Sendai virus
Yonemitsu, Y., Kitson, C., Ferrari, S., Farley, R., Griesenbach, U., Judd, D., Steel, R., Scheid, P., Zhu, J., Jeffery, P. K., et al. (2000) · Nature Biotechnology · doi:10.1038/79463 · Cited by 244
Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer
Hermanson, D. L., Bendzick, L., Pribyl, L., McCullar, V., Vogel, R. I., Miller, J. S., Geller, M. A., & Kaufman, D. S. (2016) · Stem Cells · doi:10.1002/stem.2230 · Cited by 242
Cho, H.-J., Lee, C.-S., Kwon, Y.-W., Paek, J. S., Lee, S.-H., Hur, J., Lee, E. J., Roh, T.-Y., Chu, I.-S., Leem, S.-H., et al. (2010) · Blood · doi:10.1182/blood-2010-02-269589 · Cited by 239
Nakanishi, M., & Otsu, M. (2012) · Current Gene Therapy · doi:10.2174/156652312802762518 · Cited by 147 · cited 1×
“It is worth noting that Se-V has huge potential in cystic fibrosis gene therapy(89,90) and AIDS vaccines(91) and is applicable for human iPSC replacement therapy.(92)”
BackgroundMacArthur, C. C., Fontes, A., Ravinder, N., Kuninger, D., Kaur, J., Bailey, M., Taliana, A., Vemuri, M. C., & Lieu, P. T. (2012) · Stem Cells International · doi:10.1155/2012/564612 · Cited by 91
Sendai virus-mediated CFTR gene transfer to the airway epithelium
Ferrari, S., Griesenbach, U., Iida, A., Farley, R., Wright, A. M., Zhu, J., Munkonge, F. M., Smith, S. N., You, J., Ban, H., et al. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302991 · Cited by 63
Takeda, A., Igarashi, H., Kawada, M., Tsukamoto, T., Yamamoto, H., Inoue, M., Iida, A., Shu, T., Hasegawa, M., & Matano, T. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.09.074 · Cited by 28
Cited by
Artificial Intelligence in Regenerative Medicine: Applications and Implications
Nosrati, H., & Nosrati, M. (2023) · Biomimetics · doi:10.3390/biomimetics8050442 · Cited by 158
iPSC Preparation and Epigenetic Memory: Does the Tissue Origin Matter?
Scesa, G., Adami, R., & Bottai, D. (2021) · Cells · doi:10.3390/cells10061470 · Cited by 110
Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies
Nath, S. C., Menendez, L., & Friedrich Ben-Nun, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316929 · Cited by 35
“The reprogramming methods can be divided into two major groups: integrative and non-integrative transfer systems [17] (Figure 1).”
BackgroundModelling Mitochondrial Disease in Human Pluripotent Stem Cells: What Have We Learned?
McKnight, C. L., Low, Y. C., Elliott, D. A., Thorburn, D. R., & Frazier, A. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147730 · Cited by 27
Metadata
- Authors
- Al Abbar, A., Ngai, S. C., Nograles, N., Alhaji, S. Y., & Abdullah, S.
- Venue
- BioResearch Open Access
- Publisher
- SAGE Publications
- Published
- 2020-04-01
- Volume
- 9
- Issue
- 1
- Pages
- 121-136
- ISSN
- 2164-7844 (ISSN-L)
- 2164-7860
- OpenAlex
- W3022480838
- Cited by
- 134
- References
- 45
- FWCI
- 3.53
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.